{
    "clinical_study": {
        "@rank": "137997", 
        "arm_group": [
            {
                "arm_group_label": "HM11260C", 
                "arm_group_type": "Experimental", 
                "description": "HM11260C 4 mg weekly sc injection"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo weekly sc injection"
            }, 
            {
                "arm_group_label": "HM11260C 6 mg/week", 
                "arm_group_type": "Experimental", 
                "description": "HM11260C 6 mg weekly sc injection"
            }, 
            {
                "arm_group_label": "HM11260C 6 mg/biweekly", 
                "arm_group_type": "Experimental", 
                "description": "HM11260C 6 mg biweekly sc injection"
            }, 
            {
                "arm_group_label": "HM11260C 8 mg/biweekly", 
                "arm_group_type": "Experimental", 
                "description": "HM11260C 8 mg biweekly sc injection"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the optimal dose and regimen of HM11260C, in\n      combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise\n      considered in stable health."
        }, 
        "brief_title": "Effect of LAPS-Exendin on Body Weight in Obese Population", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": [
                "Body Weight", 
                "Obesity"
            ]
        }, 
        "detailed_description": {
            "textblock": "Phase 2 study"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "1. Inclusion Criteria:\n\n               -  Age: 18 years to 65 years\n\n               -  Genders: male and female\n\n               -  healthy obese population\n\n               -  non-diabetes\n\n               -  stable body weight for at least 3 months prior to screening\n\n          2. Exclusion Criteria\n\n               -  Pregnant or nursing (lactating) women\n\n               -  Drug-induced obesity\n\n               -  Diabetes mellitus (type 1, 2, and other)\n\n               -  Previous surgical treatment for obesity\n\n               -  Any known history of severe gastrointestinal (GI) disease or intolerance\n\n               -  Known history of pancreatitis with presence of raised serum amylase and lipase\n\n               -  History of suicide attempts or recent history (within 2 years prior to\n                  screening) of major depression, anxiety, or other psychiatric disease requiring\n                  treatment with prescription medication including selective serotonin reuptake\n                  inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitor s (SNRIs),\n                  antipsychotics, and lithium."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02075281", 
            "org_study_id": "HM-EXC-205"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "HM11260C", 
                    "HM11260C 6 mg/week", 
                    "HM11260C 6 mg/biweekly", 
                    "HM11260C 8 mg/biweekly"
                ], 
                "description": "Glucagon-like peptide-1 analogue", 
                "intervention_name": "HM11260C", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "contact": {
                "email": "clinicl4@hanmi.co.kr", 
                "last_name": "Hanmi pharmaceutical Hanmi pharmaceutical"
            }, 
            "facility": {
                "address": {
                    "city": "Los angeles", 
                    "country": "United States", 
                    "state": "California"
                }, 
                "name": "Hanmi pharmaceutical"
            }, 
            "investigator": {
                "last_name": "Hanmi pharmaceutical Hanmi pharmaceutical", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes", 
        "other_outcome": [
            {
                "measure": "Change from baseline in waist circumference at 20 week", 
                "safety_issue": "No", 
                "time_frame": "20 weeks after baseline"
            }, 
            {
                "description": "homeostatic model assessment", 
                "measure": "Change from baseline in \u03b2-cell function at 20 week", 
                "safety_issue": "No", 
                "time_frame": "20 week from baseline"
            }
        ], 
        "overall_contact": {
            "email": "clinicl4@hanmi.co.kr", 
            "last_name": "Hanmi Pharmaceutical Hanmi pharmaceutical", 
            "phone": "clinicl4@hanmi.co.kr"
        }, 
        "overall_contact_backup": {
            "email": "clinicl4@hanmi.co.kr", 
            "last_name": "Hanmi Pharmaceutical Hanmi pharmaceutical"
        }, 
        "overall_official": {
            "affiliation": "Hanmi pharmaceuticals", 
            "last_name": "Hanmi pharmaceuticals Hanmi pharmaceuticals", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in body weight at 20 weeks", 
            "safety_issue": "No", 
            "time_frame": "20 weeks from baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02075281"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of participants with adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "during 20 weeks of treatment and follow-up period"
            }, 
            {
                "measure": "Change from baseline in HbA1c and fasting plasma glucose level at 20 week", 
                "safety_issue": "No", 
                "time_frame": "20 weeks from baseline"
            }, 
            {
                "description": "Cholesterol level, LDL-C level", 
                "measure": "Change from baseline in blood lipid profile (e.g., cholesterol, and LDL-C level) at 20 week", 
                "safety_issue": "No", 
                "time_frame": "20 weeks from baseline"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}